» » Exenatide, placebo comparable for major adverse CV events in type 2 diabetes

Exenatide, placebo comparable for major adverse CV events in type 2 diabetes

Health
No comments yet
  1. Exenatide, placebo comparable for major adverse CV events in type 2 diabetes  Healio
  2. CV risk of AstraZeneca's Bydureon on par with placebo in large-scale study  Seeking Alpha
  3. Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile and Fewer CV Events in Patients ...  PharmiWeb.com (press release)Full coverage

posted from Health - Google News
Thank you for reading the Exenatide, placebo comparable for major adverse CV events in type 2 diabetes on Syria News Kit If you want to spread this News please include links as Source, and if this News useful please bookmark this page in your web browser, by pressing Ctrl + D on your keyboard button, Or click the share button to place it on your profile.

Latest news:

Jamal | Jamaluddin | Mas Jamal | Masterbama

Note: Only a member of this blog may post a comment.